Thursday, March 13, 2025

White House urges FDA to reconsider HCQ for treatment

Date:

Share post:

spot_img

Washington: The White House has urged the US Food and Drug Administration (FDA) to reinstate its emergency use authorization (EUA) for the anti-malaria drug, hydroxychloroquine (HCQ), for COVID-19 treatment.

Weeks ago, the FDA revoked the EUA that allowed for HCQ used to treat certain hospitalized patients with COVID-19, after the agency determined that the drug was “unlikely to be effective in treating COVID-19 for the authorized uses in the EUA”, while highlighting potential serious side effects, reports Xinhua news agency.

“White House trade adviser Peter Navarro is leading a Trump administration effort to demand the FDA reverse course,” the Washington Post said in a report on Monday. “A reversal (on HCQ) would be widely seen as bending to the political will of the White House,” the Washington Post quoted Steven Joffe, a medical ethicist at the University of Pennsylvania, as saying. (IANS)

spot_img

Related articles

Kremlin aide rejects US ceasefire plan on Ukraine

Washington, March 13: A top aide to Russian President Vladimir Putin on Thursday rejected the US plan of...

President Droupadi Murmu, PM Modi extend Holi greetings to citizens

New Delhi, March 13: President Droupadi Murmu and Prime Minister Narendra Modi extended their warm wishes to the...

Young Australians struggle with cost of living, mental health: Report

Sydney, March 13: A new report published on Thursday highlighted the growing struggles of young Australians, who are...

Home Ministry gives nod to prosecute Sisodia, Jain facing graft allegations

New Delhi, March 13: In a fresh trouble for former Delhi ministers Manish Sisodia and Satyendar Jain, facing...